Export 11 results:
Author Title [ Type(Asc)] Year
Filters: Author is Smith, Carol  [Clear All Filters]
Journal Article
W. Jaoko, Karita, E., Kayitenkore, K., Omosa-Manyonyi, G., Allen, S., Than, S., Adams, E. M., Graham, B. S., Koup, R. A., Bailer, R. T., Smith, C., Dally, L., Farah, B., Anzala, O., Muvunyi, C. M., Bizimana, J., Tarragona-Fiol, T., Bergin, P. J., Hayes, P., Ho, M., Loughran, K., Komaroff, W., Stevens, G., Thomson, H., Boaz, M. J., Cox, J. H., Schmidt, C., Gilmour, J., Nabel, G. J., Fast, P., and Bwayo, J., Safety and immunogenicity study of Multiclade HIV-1 adenoviral vector vaccine alone or as boost following a multiclade HIV-1 DNA vaccine in Africa., PLoS One, vol. 5, no. 9, p. e12873, 2010.
W. Jaoko, Nakwagala, F. N., Anzala, O., Manyonyi, G. Omosa, Birungi, J., Nanvubya, A., Bashir, F., Bhatt, K., Ogutu, H., Wakasiaka, S., Matu, L., Waruingi, W., Odada, J., Oyaro, M., Indangasi, J., Ndinya-Achola, J., Konde, C., Mugisha, E., Fast, P., Schmidt, C., Gilmour, J., Tarragona, T., Smith, C., Barin, B., Dally, L., Johnson, B., Muluubya, A., Nielsen, L., Hayes, P., Boaz, M., Hughes, P., Hanke, T., McMichael, A., Bwayo, J., and Kaleebu, P., Safety and immunogenicity of recombinant low-dosage HIV-1 A vaccine candidates vectored by plasmid pTHr DNA or modified vaccinia virus Ankara (MVA) in humans in East Africa., Vaccine, vol. 26, no. 22, pp. 2788-95, 2008.
B. L. Rivoire, Groathouse, N. A., TerLouw, S., Neupane, K. Dev, Ranjit, C., Sapkota, B. Raj, Khadge, S., Kunwar, C. B., Kunwar, C. B., Macdonald, M., Hawksworth, R., Thapa, M. B., Hagge, D. A., Tibbals, M., Smith, C., Dube, T., She, D., Wolff, M., Zhou, E., Makhene, M., Mason, R., Sizemore, C., and Brennan, P. J., Safety and efficacy assessment of two new leprosy skin test antigens: randomized double blind clinical study., PLoS Negl Trop Dis, vol. 8, no. 5, p. e2811, 2014.
I. Cebere, Dorrell, L., McShane, H., Simmons, A., McCormack, S., Schmidt, C., Smith, C., Brooks, M., Roberts, J. E., Darwin, S. C., Fast, P. E., Conlon, C., Rowland-Jones, S., McMichael, A. J., and Hanke, T., Phase I clinical trial safety of DNA- and modified virus Ankara-vectored human immunodeficiency virus type 1 (HIV-1) vaccines administered alone and in a prime-boost regime to healthy HIV-1-uninfected volunteers., Vaccine, vol. 24, no. 4, pp. 417-25, 2006.
S. Vasan, Schlesinger, S. J., Huang, Y., Hurley, A., Lombardo, A., Chen, Z., Than, S., Adesanya, P., Bunce, C., Boaz, M., Boyle, R., Sayeed, E., Clark, L., Dugin, D., Schmidt, C., Song, Y., Seamons, L., Dally, L., Ho, M., Smith, C., Markowitz, M., Cox, J., Gill, D. K., Gilmour, J., Keefer, M. C., Fast, P., and Ho, D. D., Phase 1 safety and immunogenicity evaluation of ADVAX, a multigenic, DNA-based clade C/B' HIV-1 candidate vaccine., PLoS One, vol. 5, no. 1, p. e8617, 2010.
S. Vasan, Schlesinger, S. J., Chen, Z., Hurley, A., Lombardo, A., Than, S., Adesanya, P., Bunce, C., Boaz, M., Boyle, R., Sayeed, E., Clark, L., Dugin, D., Boente-Carrera, M., Schmidt, C., Fang, Q., Huang, Y., Zaharatos, G. J., Gardiner, D. F., Caskey, M., Seamons, L., Ho, M., Dally, L., Smith, C., Cox, J., Gill, D., Gilmour, J., Keefer, M. C., Fast, P., and Ho, D. D., Phase 1 safety and immunogenicity evaluation of ADMVA, a multigenic, modified vaccinia Ankara-HIV-1 B'/C candidate vaccine., PLoS One, vol. 5, no. 1, p. e8816, 2010.
C. Parnes, Guillermin, J., Habersang, R., Nicholes, P., Chawla, V., Kelly, T., Fishbein, J., McRae, P., Goessler, M., Gatti, A., Calcagno, J. A., Eki, C., Harris, K. A., Joyave, J., McFarland, K., Protter, P., Sullivan, M., Stanford, A., Lovett, N., Ortiz, M., Rojas, S., Cyrus, S., Cyrus, J., Cohen, S., Buchin, D., Riordan, L., Zuniga, M., Shah, R., Minard, C., Quintin, A., Douglas, G., van Houten, J., Freutner, S., Chartrand, S., Nowatzke, P., Romero, J., Rhodes, T., Benoit, M., Walter, E., Walker, L., DeBonnett, L., Cross, M., Free, T., Martin, S., Shank, K., Guedes, B., Atkinson, L. Ann, Halpin, G. J., Rouse, K., Hand, I., Geiss, D., Marshall, J. R., Burleson, L., Boland, J., Seybold, K., Hunter, V., Unfer, S., Schmucker, J., Gley, M., Marcus, M., Thompson, P., Milla, P., Young, C., Zanni, R., Zinno, V., Fetter-Zarzeka, A., Busey, A., Sokunbi, M. A., Airington, S., Richard, N., Muraligopal, V., Lewis, S., F Weber, T., Giordano, B. P., Linehan, D., Roach, J., Davis, R., Rzepka, A. A., Booth, T., Smeltzer, D., Walsh, J., Arispe, E., Rowley, R., Bolling, C., Botts, T., Haskett, K., Raby, D., Batiz, E., Gelfand, A., Farrell, L., Butler, S., Colby, L., Schochet, P., Bentler, J., Hirsch, D., Wilkinson, L., Aaronson, A., Bennett, E., Wingate, J., Quinn, D., Komendowski, K., Deckard, M., Frogel, M., Nerwen, C., Copenhaver, S., Prater, M., Wolsztein, J., Mackey, K., Benbow, M., Naranjo, M., Hensley, S., Hayes, C., Sadeghi, H., Lawson, S. May, McCall, M., Combs, K., Ledbetter, J., Sarnosky, K., Swafford, C., Speer, M., Barton, W. J., Mink, J. W., Lemm, D., Hudak, M., Case, E., Rowen, J., Fuentes, S., Pane, C., Richardson, L., Chavarria, C., Cassino, D., Ghaffari, K., Carroll, C., Lee, H., Guclu, L., Johnson, C., Blum, V., Boron, M. L., Sorrentino, M., Hirsch, R. L., Van Veldhuisen, P. C., and Smith, C., Palivizumab prophylaxis of respiratory syncytial virus disease in 2000-2001: results from The Palivizumab Outcomes Registry., Pediatr Pulmonol, vol. 35, no. 6, pp. 484-9, 2003.
S. Vasan, Hurley, A., Schlesinger, S. J., Hannaman, D., Gardiner, D. F., Dugin, D. P., Boente-Carrera, M., Vittorino, R., Caskey, M., Andersen, J., Huang, Y., Cox, J. H., Tarragona-Fiol, T., Gill, D. K., Cheeseman, H., Clark, L., Dally, L., Smith, C., Schmidt, C., Park, H. H., Kopycinski, J. T., Gilmour, J., Fast, P., Bernard, R., and Ho, D. D., In vivo electroporation enhances the immunogenicity of an HIV-1 DNA vaccine candidate in healthy volunteers., PLoS One, vol. 6, no. 5, p. e19252, 2011.
B. S. Graham, M McElrath, J., Keefer, M. C., Rybczyk, K., Berger, D., Weinhold, K. J., Ottinger, J., Ferarri, G., Montefiori, D. C., Stablein, D., Smith, C., Ginsberg, R., Eldridge, J., Duerr, A., Fast, P., and Haynes, B. F., Immunization with cocktail of HIV-derived peptides in montanide ISA-51 is immunogenic, but causes sterile abscesses and unacceptable reactogenicity., PLoS One, vol. 5, no. 8, p. e11995, 2010.
P. F. Wright, Mestecky, J., M McElrath, J., Keefer, M. C., Gorse, G. J., Goepfert, P. A., Moldoveanu, Z., Schwartz, D., Spearman, P. W., Habib, R. El, Spring, M. D., Zhu, Y., Smith, C., Flores, J., and Weinhold, K. J., Comparison of systemic and mucosal delivery of 2 canarypox virus vaccines expressing either HIV-1 genes or the gene for rabies virus G protein., J Infect Dis, vol. 189, no. 7, pp. 1221-31, 2004.
C. Schmidt, Smith, C., Barin, B., Bakhtyari, A., Bart, P. - A., Bekker, L. - G., Chomba, E., Clumeck, N., Ho, D., Hoosen, A., Jaoko, W., Kaleebu, P., Karita, E., Keefer, M. C., van Lunzen, J., McMichael, A., Mehendale, S., Peters, B., Ramanathan, V. D., Robinson, A., Rockstroh, J., Vardas, E., Vets, E., Weber, J., Graham, B. S., Than, S., Excler, J. - L., Kochhar, S., Ho, M., Heald, A., and Fast, P. E., Background morbidity in HIV vaccine trial participants from various geographic regions as assessed by unsolicited adverse events., Hum Vaccin Immunother, vol. 8, no. 5, pp. 630-8, 2012.